Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study

NCT00453427 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT00453427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00453427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2006
Completion date
May 31, 2015
Enrollment
20 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphomas